Ahead of Catalyst (CPRX) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Core Insights - Analysts project Catalyst Pharmaceutical (CPRX) will report quarterly earnings of $0.42 per share, reflecting a 40% decline year over year [1] - Revenue estimates for the quarter are set at $140.02 million, indicating a 1.3% decrease from the same period last year [1] - There have been no revisions in the consensus EPS estimate over the last 30 days, suggesting stability in analysts' forecasts [1] Revenue Projections - Analysts expect 'Revenues- Product revenue, Net- FIRDAPSE' to be $96.43 million, representing a year-over-year increase of 16.9% [4] - The consensus for 'Revenues- Product revenue, Net- FYCOMPA' is $12.28 million, indicating a significant decline of 67.9% year over year [4] - For 'Revenues- Product revenue, Net- AGAMREE', analysts project $31.30 million, reflecting a year-over-year increase of 48.5% [4] Overall Performance - The average prediction for 'Revenues- Product revenue, net' stands at $140.01 million, showing a year-over-year change of -1.3% [5] - Over the past month, Catalyst shares have gained 0.5%, while the Zacks S&P 500 composite has decreased by 1% [5] - Catalyst holds a Zacks Rank of 3 (Hold), suggesting its performance is expected to align with the overall market in the near term [5]